Ranked by MELANY · Oct 2026
Healthcare Stocks, Rated
Healthcare spans large pharmaceutical companies, device makers, diagnostics, distributors and insurers. Demand is among the least cyclical in the market, which is why the sector is treated as defensive, but the policy risk is among the highest.
Every score on this page is free. 20 healthcare stocks scored on the same eight factors, updated as the data changes.
MELANY rankingRatings as of 2026-10-07Healthcare Stocks
Ranked by composite score
Ranked highest to lowest by MELANY composite score, a 0 to 100 reading from eight factors. Each row links to the full breakdown and the live price. Ratings are a dated snapshot, most recently computed 2026-10-07.
These tiers are algorithmic research readings, not a recommendation to buy or sell any security, and not personalized investment advice. Ranking order is not a suggested purchase order.
What is in the app for these 20 companies
The score and the eight factors behind it are open on every company page. The trade plan is the part that is not: one suggested entry price per company, the stop, the targets, and an alert when a name enters its entry zone. That is part of Market Eyes Pro, and the first 30 days are free.
What moves this group
Patent expiry is the dominant long-term driver for pharmaceutical companies: a large product losing exclusivity can remove years of growth. Device makers follow procedure volumes and hospital capital budgets. Insurers are driven by the medical loss ratio, which is how much of each premium dollar goes out as claims. Drug pricing policy is the sector-wide risk.
Also searched as: healthcare sector stocks, pharmaceutical companies, medical device makers, health insurers.
How Market Eyes Live scores these companies
Every company on this page is scored by MELANY, our own engine, which reads regulatory filings and market data and produces a composite score from 0 to 100 across eight factors: valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile and macro fit.
Each score maps to a conviction tier rather than a buy or sell call. Established companies with enough financial history are judged on fundamentals. Pre-profit or thin-data companies are judged on a separate speculative path that leans on momentum and theme strength, because there are not enough fundamentals to read. That is why two names with similar scores can carry very different risk.
The engine is not new to being tested. MELANY's risk and portfolio rules are stress-tested across 19 years of U.S. market history, from 2007 to 2026, spanning the 2008 financial crisis, the 2020 COVID crash and the 2022 bear market, and the test set includes companies that later delisted so the results are not flattered by survivorship. Every rating it publishes is also recorded and graded every day against what the market does next. The full methodology and the validation study are public: how MELANY is tested and the MELANY validation study, Working Paper No. 01.
Frequently asked questions
Is healthcare a defensive sector?
Demand is relatively stable through the economic cycle, which is the usual reason for calling it defensive. That does not make individual names low risk, particularly around patent expiry and policy changes.
What is a patent cliff?
The point where a drug loses exclusivity and generic competition removes most of its revenue. It is the single largest scheduled risk in large-cap pharma.
How current is this list?
Each row shows the date its rating was computed, and the list refreshes on a rolling schedule.
Other sectors and themes
Market Eyes Live
The scores stay free. The entry prices are in Pro, 30 days free.
MELANY rates every U.S. stock and ETF, PRISM ranks conviction and APEX writes the plan with one entry zone. Every rating is graded in public.